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Abstract
Gemcitabine is a cytotoxic cytidine analog, which is widely used in anti-cancer therapy. One mechanism by which
gemcitabine acts is by inhibiting nucleotide excision repair (NER). Recently NER was implicated in Gadd45 mediated DNA
demethylation and epigenetic gene activation. Here we analyzed the effect of gemcitabine on DNA demethylation. We find
that gemcitabine inhibits specifically Gadd45a mediated reporter gene activation and DNA demethylation, similar to the
topoisomerase I inhibitor camptothecin, which also inhibits NER. In contrast, base excision repair inhibitors had no effect on
DNA demethylation. In Xenopus oocytes, gemcitabine inhibits DNA repair synthesis accompanying demethylation of oct4.I n
mammalian cells, gemcitabine induces DNA hypermethylation and silencing of MLH1. The results indicate that gemcitabine
induces epigenetic gene silencing by inhibiting repair mediated DNA demethylation. Thus, gemcitabine can function
epigenetically and provides a tool to manipulate DNA methylation.
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Introduction
Gemcitabine (29deoxy-2929-difluorocytidine monohydrochlor-
ide, GEMZAR) is one of the most widely used anti-cancer drugs
and is particularly effective against solid tumors [1]. Pioneering
work from the Plunkett laboratory showed that gemcitabine is a
pro-drug, which after intracellular uptake is metabolized to
gemcitabine diphosphate and triphosphate, whose incorporation
into DNA results in chain termination by inhibiting DNA
polymerase activity [2,3]. Unlike its analog cytosine arabinoside,
which causes immediate termination of DNA polymerization,
gemcitabine allows limited nucleotide polymerization by a process
termed masked chain termination, which prevents exonucleases
from excising the aberrant gemcitabine nucleotide [4,5]. Incor-
porated gemcitabine can be recognized by p53 and DNA
dependent protein kinase, which may induce apoptosis [6].
Gemcitabine also potently inhibits ribonucleotide reductase,
resulting in a decrease of competing deoxyribonucleotide pools
necessary for DNA synthesis [5,7,8]. Thus, gemcitabine inhibits
DNA synthesis by at least two different modes. Gemcitabine can
also induce increased ligase I levels [9].
Gemcitabine is frequently used in combination with cisplatin,
which forms DNA adducts, that can be repaired by nucleotide
excision repair (NER). The synergistic action of both drugs is
thought to reside in an inhibitory effect of gemcitabine on the repair
of the DNA lesions induced by cisplatin [10,11,12]. The current
model is that gemcitabineinhibits DNArepairsynthesis, which is an
obligatory step in NER and thereby potentiates cisplatin effects.
Recently, we have implicated NER in the removal of 59-
methylcytosine (5mC) from DNA during active DNA demethylation
[13]. In DNA of metazoa, 5mC is a common epigenetic mark
associated with gene silencing, whichcan be reversed by active DNA
demethylation. We showed that Growth Arrest and DNA Damage
inducible protein 45 a (Gadd45a) is a key mediator of active DNA
demethylation [13]. Gadd45a binds directly to and requires
the activity of Xeroderma pigmentosum complementation group
protein G (XPG), a 39endonuclease of the NER complex. We
therefore suggested a model where Gadd45a is targeted to specific
sites of demethylation and recruits the DNA repair machinery.
Methylated cytosinesarethenexcised andreplaced byunmethylated
nucleotides [13].
Since gemcitabine inhibits NER, it was of interest if it also
affects DNA methylation. Here we tested this possibility and find
that gemcitabine inhibits specifically Gadd45a mediated reporter
gene activation. Moreover, gemcitabine inhibits unscheduled
DNA synthesis in methylated oct4 plasmid in Xenopus oocytes.
Finally, it induces hypermethylation and inhibits expression of
MLH1. The results therefore indicate a new epigenetic mode of
gemcitabine action.
Results and Discussion
We first examined gemcitabine along with other cytotoxic drugs
in a methylation sensitive reporter assay, where we monitored
Gadd45a-mediated re-activation of an in vitro methylated – and
hence silenced - Gal-responsive luciferase reporter plasmid [13].
The Gal4 reporter system is based on the ability of GAL4-Elk1
fusion protein to specifically bind and activate a Gal4 driven
luciferase gene [14,15]. Camptothecin and b-lapachone are
inhibitors of topoisomerase I, an enzyme required during DNA
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erase II, which is not involved in NER or base excision repair
(BER) [17,18].
All three DNA repair inhibitors, gemcitabine, camptothecin and
b-lapachone inhibited Gadd45a-mediated activation of the reporter
(Fig. 1A). In contrast, the topoisomerase II inhibitors etoposide
and merbarone had little effect. Importantly, activation of the
same methylated reporter plasmid by the transcriptional activator
Gal-Elk1 (Fig. 1B) as well as activation of the cotransfected Renilla
luciferase reporter plasmid used for normalization (not shown),
were unaffected by the DNA repair inhibitors, ruling out
unspecific inhibitory effects of these compounds on transcription
and/or translation. Furthermore, an in vitro methylated EGFP
reporter plasmid under the control of the oct4 regulatory region
fused to the thymidine kinase promoter was transcriptionally
activated by Gadd45a as monitored by the re-expression of EGFP
(Fig. 1C). This re-activation was also impaired by gemcitabine
treatment.
To directly test if this transcriptional repression by gemcitabine
is indeed due to DNA hypermethylation, we monitored methyl-
ation levels using methylation sensitive Southern blotting.
Untransfected in vitro methylated reporter plasmid was expectedly
Figure 1. Gemcitabine inhibits Gadd45a mediated gene activation. (A–B) Luciferase reporter assays of HEK293T cells transiently transfected
with HpaII in vitro methylated Gal-responsive reporter, together with either Gadd45a (A) or Gal-Elk1 (B, specificity control). Cells were treated with
DMSO (control, Ctrl), gemcitabine (Gem), camptothecin (Cpt), etoposide (Eto), b-lapachone (bLap), merbarone (Mer) as indicated. Shown is the fold
activation by Gadd45a (A) or Gal-Elk1 (B) over control transfected cells. Error bars represent standard deviation. Significance was assessed via
unpaired Student’s t-test using the control sample as reference: ** =p,0.01. (C) Western blot analysis of EGFP expression. Whole cell extracts of
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digested by the methylation insensitive isoschizomer MspI
(Fig. 2A). Following transfection, the reporter was mostly HpaII
insensitive, while its co-transfection with Gadd45a induced HpaII
sensitivity, indicating DNA demethylation. Treatment with
gemcitabine impaired this demethylation.
To independently corroborate these results, we employed
bisulfite sequencing. We first confirmed that the reporter was
initially fully methylated (Fig. S1). Sequencing of the reporter
recovered from transfected cells revealed, interestingly, some
spontaneous demethylation. Gadd45a overexpression induced
substantial demethylation of the EGFP reporter, most pronounced
(two-fold) at the site -299 (Fig. 2B). Importantly, gemcitabine
treatment reversed this effect resulting in methylation levels
comparable to control without Gadd45, and also reduced
endogenous demethylation. These results supports that gemcita-
bine inhibits Gadd45a mediated DNA demethylation. Further-
more, since endogenous demethylation is also gemcitabine
sensitive this may involve endogenous Gadd45a and NER.
Besides NER, a base excision repair-based mechanism (BER)
has been implicated in active DNA demethylation in mammalian
cells [19,20,21]. Moreover, Gadd45a may also affect BER in
addition to its effect on NER [19,22]. Since BER also requires
DNA synthesis, the question arose if gemcitabine may function as
a BER inhibitor. We therefore tested bona fide BER inhibitors.
CRT 0044876 (CRT) and betulinic acid (Bet) are inhibitors of AP
Endonuclease I, [23] and DNA Polymerase b [24], respectively,
both of which are key enzymes in BER. Furthermore, ABT-888
(ABT) blocks PARP-1, a sensor of single and double strand breaks
during BER [25]. Remarkably, none of these compounds affected
Gadd45a mediated demethylation of the pOctTK-EGFP reporter as
assessed by methylation sensitive PCR (Fig. 3). This suggests that
BER does not play a role in Gadd45a mediated demethylation, at
least in this context. Under the same conditions, camptothecin
(Cpt) as well as gemcitabine (Gem) blocked the Gadd45a induced
DNA demethylation as well as endogenous demethylation, again
supporting a NER model for Gadd45a demethylation.
DNA demethylation can theoretically also occur in a passive
manner if the reporter plasmid is repetitively replicated. To
experimentally rule out this scenario in our reporter system, we
performed methylation sensitive PCR assaying the bacterial
methylation state of the transfected plasmid (Fig. S2). A single
ClaI recognition site in the backbone of pOctTK-EGFP is also target
for bacterial Dam methylation. Bacterial Dam methylation blocks
ClaI restriction at this site. During replication in eukaryotic cells,
the bacterial methylation would be diluted if the plasmid was
replicating and would gain ClaI sensitivity. While the reporter
from dam
2 cells was sensitive to ClaI, the pOctTK-EGFP from dam
+
E.coli remained resistant to ClaI digest 65 h after transfection and
thus was not replicated in the transfected cells. Hence, Gadd45
mediated demethylation is replication-independent and therefore
active.
We showed previously that Gadd45a is required for DNA
demethylation of the oct4 promoter in Xenopus oocytes. This
demethylation is accompanied by unscheduled DNA repair
synthesis, since Bromo-deoxyuridine (BrdU) is incorporated into
methylated but not unmethylated oct4 plasmid [13]. Xenopus
oocytes are resting cells, and hence BrdU incorporation cannot be
due to replication but rather be related to DNA repair processes.
We therefore tested if this unscheduled DNA repair synthesis is
sensitive to gemcitabine. BrdU was coinjected in oocytes with
methylated oct4 plasmid with or without gemcitabine. After 0, 12,
or 36 h, plasmid DNA was immunoprecipitated with anti-BrdU
antibodies and analyzed by PCR. The amount of PCR product
obtained is a measure of BrdU incorporation and hence, DNA
synthesis. In control samples, a progressive PCR product increase
is observed with time (Fig. 4, lanes 2–4) [13]. Significantly,
gemcitabine treatment almost completely abolished this BrdU
incorporation (lanes 6–8). This result suggests that gemcitabine
inhibits DNA repair synthesis associated with DNA demethylation.
As a caveat, we cannot rule out the possibility that the reduced
PCR product after BrdU immunoprecipitation is due to an
inhibitory effect of Gemcitabine or its metabolites on Taq DNA
polymerase. However, our data obtained by various methods
(methylation-sensitive PCR, Southern blotting, bisulfite sequenc-
ing) argue that the effects of gemcitabine are rather due to
inhibition of DNA repair.
Next, we analyzed the effect of gemcitabine on methylation of
endogenous loci and first examined global methylation levels. The
bulk of 5mC in the genome is associated with telomeres and
repetitive DNA, rather than transcribed genes. As cancer is often
associated with global DNA hypomethylation, in particular
hypomethylated chromosome 1 satellite 2 repetitive elements
(C1S2) [26,27], we analyzed the effect of gemcitabine on the
methylation of these elements. Gemcitabine did not alter C1S2
methylation in HEK293 or MCF7 cells at any tested concentra-
tion or at any time point analyzed (18–42 h after treatment, data
not shown) (Fig. 5A–B). This was surprising, since we previously
reported that Gadd45a induces C1S2 demethylation and global
hypomethylation. However, using improved experimental condi-
tions we now found that Gadd45a overexpression does not induce
significant C1S2 demethylation or global hypomethylation in
HCT116 cells, unlike the demethylating drug 5-aza-29-deoxycy-
tidine (AZA) (Fig. 5C–D). Rather, the major demethylation effect
of Gadd45 appears to be restricted to single copy genes ([19,28,29]
and our unpublished data).
We therefore analyzed the effect of gemcitabine on DNA
methylation of an endogenous single-copy gene. The promoter of
MLH1 is a well studied methylation regulated gene which is kept
partially unmethylated by Gadd45a [13]. Treating HEK293 and
MCF7 cells with increasing amounts of gemcitabine led to a
significant hypermethylation of the MLH1 promoter as assessed by
methylation-sensitive PCR (Fig. 6A). This increase in methylation
was accompanied by reduced MLH1 expression (Fig. 6B). In
contrast, etoposide was without significant effect.
Epigenetic therapy is becoming an increasingly important
strategy for cancer treatment since cancer cells show genome
wide epigenetic alterations. For example, many tumor suppressor
genes are hypermethylated while the bulk of the genome is
hypomethylated [30,31]. However, clinical drugs affecting DNA
methylation are limited to 5-azacytidine (Vidaza) and its derivative
5-aza-29-deoxycytidine (decitabine, Dacogen), both of which
induce DNA hypomethylation (reviewed in [32]). Previously it
was shown that a number of cytotoxic anticancer drugs which
block DNA replication induce DNA hypermethylation. It was
proposed that this effect is due to methylation of CpGs at stalled
replication forks, which would normally not be methylated
[33,34]. However, the doses required in these experiments were
in the micro- to millimolar range, and thus 1000x higher than the
doses used in our experiments. Therefore the physiological- or
clinical relevance of this ‘‘cytotoxic hypermethylation’’ effect is
unclear. Unlike ‘‘cytotoxic hypermethylation’’, gemcitabine did
not affect global DNA methylation and did not markedly inhibit
cell proliferation at the doses used in our experiments (data not
shown).
Our results rather support a model where gemcitabine functions
by inhibiting NER and thereby DNA demethylation, thus leading
to gene silencing. We therefore propose that gemcitabine besides
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e14060Figure 2. Gemcitabine impairs Gadd45a mediated demethylation. (A) Methylation-sensitive Southern blot. HpaII in vitro methylated plasmid
pOctTK-EGFP was recovered from HEK293T cells after transient co-transfection with Gadd45a or pBl-KS (control), with 65 h gemcitabine treatment as
indicated. Recovered plasmids were digested with the indicated restriction enzyme and the products analyzed by Southern blot using a GFP probe.
(B) Bisulfite sequencing analysis of five HpaII sites within the pOctTK regulatory region upon transient transfection and treatment as in (A). White and
black circles, unmethylated, methylated CpG, respectively. Arrow marks EGFP translation start site.
doi:10.1371/journal.pone.0014060.g002
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methylation, which has consequences for the understanding of
its effect in cancer therapy. For example, MLH1 is a tumor
suppressor and the fact that its expression is silenced by
gemcitabine may be an undesirable effect in cancer treatment.
More generally, gemcitabine may be a useful tool to specifically
interfere with Gadd45 mediated DNA demethylation in biological
processes ranging from embryonic gene activation to adult
neurogenesis [19,29].
Materials and Methods
Tissue culture and transfection
HEK293, HEK293T, MCF7 and RKO cells (ATCC numbers:
CRL-1573, CRL-11268, HTB-22, CRL-2577, respectively) were
grown at 37uC in 10% CO2 (5% CO2 for RKO cells) in
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% fetal calf
serum, 2 mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. HCT116 cells (ATCC number: CCL-247) were
cultured at 37uC under 10% CO2 in McCoy’s 5A medium
supplemented as described above. Transient DNA transfections
were carried out using FuGENE6 (Roche) following the
manufacturer instructions. For MLH1 and C1S2 methylation
analysis, cells were treated with 34, 67 or 134 nM gemcitabine (Eli
Lilly) or 43 nM etoposide (Sigma Aldrich) for 18 h or with
500 nM 5-aza-29-deoxycytidine (AZA, Sigma) for 42 h before
harvesting. For methylation-sensitive Southern blotting and
bisulfite sequencing, cells were transfected on 10 cm dishes with
1.2 mg pBl-KS control plasmid or Gadd45a along with pOctTK-
EGFP. 3 h after transfection, cells were treated with 134 nM
gemcitabine for 65 h. For methylation-sensitive PCR of pOctTK-
EGFP at HpaII site 2299, cells were transfected in 6-well dishes
Figure 3. Gadd45a mediated DNA demethylation is unaffected by BER inhibitors. Methylation status of the HpaII site 2299 (see Fig. 2B) in
the pOctTK-EGFP regulatory region was assayed by methylation sensitive PCR 48 h after transient co-transfection with or without hGadd45a. Cells
were treated with the topoisomerase II inhibitor etoposide (Eto), the NER inhibitors gemcitabine (Gem) and camptothecin (Cpt), or the BER inhibitors
CRT 0044876 (CRT), betulinic acid (Bet) and ABT-888 (ABT) as indicated. Untransfected unmethylated (non-me) and HpaII in vitro methylated reporter
plasmid (me) served as reference. Significance was assessed via unpaired Student’s t-test using the untreated Gadd45a transfected sample as
reference: * =p,0.05; ** =p,0.01; *** =p,0.001.
doi:10.1371/journal.pone.0014060.g003
Figure 4. Gemcitabine inhibits unscheduled DNA synthesis of methylated DNA. Methylated oct4 plasmid was injected with or without
BrdU into Xenopus oocytes in presence or absence of gemcitabine (Gem) and recovered after incubation (see diagram). To control for equal loading,
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200 ng pOctTK-EGFP using Turbofect transfection reagent
(Fermentas) following the manufacturer instructions. Immediately
after transfection, cells were treated with 50, 100 or 150 nM
gemcitabine, 15, 25 or 50 nM camptothecin (MP Biomedicals),
50, 100 or 200 mM CRT 0044876 (Sigma Aldrich), 1, 5 or 10 mM
betulinic acid (Sigma Aldrich), 5, 10 or 20 mM ABT-888 (Tebu
Bio) or 10, 20 or 40 nM etoposide (Sigma Aldrich) for 48 h.
Luciferase reporter assay
Dual-Luciferase reporter assays (Promega) were performed 40 h
after transient DNA transfection of HEK293T cells in 96-well
plates with a total of 110 ng DNA per well, containing 5 ng firefly
luciferase reporter, 5 ng pBS or 5 ng Xenopus tropicalis Gadd45a
plasmid, 0.1 ng Renilla luciferase reporter plasmid and 100 ng
pBS. Reporter plasmids were produced in the dam
2/dcm
2 bacteria
strain SCS110 and in vitro methylated using the HpaII- and HhaI-
methylase. Transfections were performed in triplicate. Where
indicated, cells were treated with 67 nM gemcitabine, 26 nM
camptothecin (MP Biomedicals), 43 nM etoposide (Sigma-Al-
drich), 30 nM b-lapachone (Calbiochem) or 20 nM merbarone
(Calbiochem) for 18 h. Results are shown as the mean of triplicates
and error bars indicate standard deviation. Experiments were
repeated three times.
Quantitative RT-PCR (qPCR)
RNA was isolated using the RNeasy Kit (Qiagen) and reverse
transcribed with the SuperScript II reverse transcriptase (Invitro-
gen). Real-Time PCR was performed using Roche LightCycler480
probes master and primers in combination with predesigned
mono-color hydrolysis probes of the Roche Universal probe
library (UPL). The following primers and UPL probes were
designed at https://www.roche-applied-science.com/sis/rtpcr/
upl/adc.jsp. hMLH1 forward 59- GAATGCGCTATGTTC-
TATTCCA, reverse 59-ATGGAGCCAGGCACTTCA, UPL
probe #38. For quantification Roche LC480 relative quantifica-
tion software module was used. All values were normalized to the
level of the housekeeping gene GAPDH.
Analysis of DNA methylation
Genomic DNA (gnDNA) from treated cells or transfected
reporter plasmids were prepared using the Blood & Tissue kit
(Qiagen). The DNA was split into three parts and either digested
with PvuII, HpaII or its methylation insensitive isoschizomer
MspI. Methylation was determined by comparing HpaII digested
versus PvuII control digested DNA samples via qPCR using
methylation sensitive PCR primers (HpaII hMLH1 forward, 59-
CCTCAGCAGAGGCACACA; reverse, 59- CGGGGAATAC-
GAAATATCCA in combination with SYBR green; HpaII
pOctTK -299 forward, 59- ATAACCAGCCACCTTGATCTG;
reverse, 59- ATTCGCCAATGACAAGACG in combination with
Roche UPL probe #39). As internal normalization control, a PCR
using methylation insensitive primers (for gnDNA: forward, 59-
CTCCAACTCAGGGCCTACAC; reverse, 59-CCAGGCTTT-
TGTGGCCTAT in combination with SYBR green; for pOctTK
plasmid: forward, 59-ACTGCATCTCCCTTTCCTTGT; re-
verse, 59-GCCCCCTGCAAGTCTTTT in combination with
Roche UPL probe #137) was performed (data not shown). MspI
digest served as control for an intact restriction enzyme
Figure 5. Gemcitabine does not affect global methylation
levels. (A–B) Methylation of chromosome 1 satellite 2 (C1S2) in
HEK293 (A) or MCF7 cells (B) was analyzed by combined bisulfite
restriction analysis (COBRA). Note that neither gemcitabine (Gem, 33–
134 nM) nor etoposide (Eto, 43 nM) treatment affect C1S2 methylation.
C1S2 methylation of RKO cells (A, right) and HCT116 cells (116, B, right)
serve as control for high C1S2 methylation. U, undigested (unmethy-
lated) PCR amplicon; M, digested (methylated) restriction fragment. (C)
COBRA analysis of C1S2 methylation in HCT116 cells as in (A, B). Cells
were transfected with X. tropicalis Gadd45a (xtGadd45a) or treated with
5-aza-29-deoxycytidine (AZA). U, undigested (unmethylated) PCR
amplicon; M, digested (methylated) restriction fragment. (D) Capillary
electrophoresis (CE) of DNA 5-methylcytosine (5mC). HCT116 cells were
either treated with AZA or transiently transfected with X. tropicalis
Gadd45a (xtGadd45a). After 48 h 5mC levels were determined by CE.
Error bars represent standard deviation. Significance was assessed via
Student’s t-test using the untreated sample as reference: * =p,0.05.
doi:10.1371/journal.pone.0014060.g005
GEMZAR Blocks Demethylation
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tion of the promoter of the unmethylated GAPDH housekeeping
gene containing two HpaII sites (data not shown) or the
unmethylated reporter plasmid was performed.
COBRA was performed as described [35]. Genomic DNA
methylation levels were determined by capillary electrophoretic
analysis, as described [36].
Methylation-sensitive Southern blotting was performed as
described previously [13]. For bisulfite sequencing, the transfected
pOctTK-EGFP reporter plasmid was recovered from the cells using
alkaline lysis as described [37], subjected to another round of
purification using the DNA MiniPrep Kit (Qiagen). The recovered
plasmid DNA was linearized by NotI restriction digest and 500 ng
DNA were bisulfite converted using the Epitect Kit (Qiagen).
2.5 ml of the converted DNA was used as template for PCR
amplification using Accuprime Taq DNA polymerase (Invitrogen)
and the following primers: forward, 59 GATTTGTTTTG-
TAGGTGGAGAGTTT; reverse, AAATAAACTTCAAAAT-
CAACTTACC. The PCR product was cloned using the TA
cloning kit (Invitrogen) and single clones sent for sequencing. The
experiment was reproduced three times with very similar results.
BrdU incorporation in Xenopus oocytes
BrdU incorporation assays were performed essentially as
described [13]. 5 fmol gemcitabine was injected with 5 pmol
BrdU and 10 pg HpaII/HhaI in vitro methylated oct4 plasmid.
Figure 6. Gemcitabine induces hypermethylation and silencing of MLH1. (A) Methylation sensitive PCR analyzing MLH1 promoter
methylation state in MCF7 or HEK293 cells. Cells were treated as indicated with increasing concentrations of gemcitabine (Gem, 33–134 nM) or
etoposide (Eto, 43 nM) as control. HpaII restriction is methylation sensitive and allows the quantification of the MLH1 methylation state. As control,
samples werealso treated withthe methylationinsensitive isoschizomerMspI.Error barsrepresent thestandarddeviation of threebiological replicates.
Significance was assessed via unpaired Student’s t-test using the untreated sample as reference: * =p,0.05; ** =p,0.01. (B) Cells were treated as in
(A). Relative expression of MLH1 normalized to GAPDH was monitored by qPCR. Error bars represent the standard deviation of three biological
replicates. Significance was assessed via unpaired Student’s t-test using the untreated sample as reference: * =p,0.05; ** =p,0.01; *** =p,0.001.
doi:10.1371/journal.pone.0014060.g006
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after injection. BrdU-labeled control DNA (BrdU-Luc) generated
by nick-translation was added during lysis to monitor the
immunoprecipitation.
Supporting Information
Figure S1 Full in vitro methylation of the pOctTK-EGFP reporter
plasmid. Bisulfite sequencing analysis of five HpaII sites within the
pOctTK-EGFP reporter upon in vitro methylation using HpaII
methylase. The sequencing reveals that the plasmid used for
transient transfection in Figure 1C, 2A and B was fully in vitro
methylated. Therefore, changes upon transfection are indicative
for endogenous DNA demethylation. White and black circles,
unmethylated, methylated CpG, respectively. Arrow marks GFP
translation start site.
Found at: doi:10.1371/journal.pone.0014060.s001 (1.64 MB EPS)
Figure S2 pOctTK-EGFP reporter plasmid does not replicate
during DNA demethylation. For these experiments, the transfect-
ed reporter plasmid was amplified using Dam methylase positive
E. coli (dam+). The HpaII in vitro methylated reporter was then
transiently transfected with or without hGadd45a in presence or
absence of gemcitabine (Gem, 150 nM). 65 h after transfection the
reporter was recovered for methylation sensitive PCR. Shown are
the results of two independent experiments (exp. 1 and 2).
Untransfected reporter plasmids that were either unmethylated
(HpaII non-me) or HpaII in vitro methylated (dark grey bars)
served as reference. They were either amplified in dam+ cells or in
dam negative E. coli (dam-) as indicated. (A) HpaII methylation
sensitive PCR. In agreement with Figure 3, the in vitro methylated
CpG at position -299 is demethylated by hGadd45a. Note: the
lower overall methylation level compared to Figure 3 is due to the
longer incubation time of 65 h versus 48 h. As expected, the
untransfected HpaII in vitro methylated plasmid is resistant to
HpaII digest, whereas non-methylated is fully digested. (B) ClaI
methylation sensitive PCR. A single ClaI recognition site
(ATCGAT) in the backbone of pOctTK is also target for bacterial
Dam methylation. Overlapping bacterial Dam methylation blocks
ClaI restriction at this site. During replication in eukaryotic cells,
the bacterial methylation would be diluted if the plasmid was
replicated and would gain ClaI sensitivity. Accordingly, the
untransfected reporter from dam- cells is sensitive to ClaI.
However, the transfected pOctTK from dam+ E. coli remains as
resistant to ClaI digest as the untransfected plasmid (dark grey bar,
dam+). This is expected for a non-replicating plasmid.
Found at: doi:10.1371/journal.pone.0014060.s002 (3.10 MB EPS)
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